Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Holtzman
Washington University, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eli Lilly and Company
Other : Licensing from awardee institu
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Holtzman’s personal financial relationship with Eli Lilly and Company (Lilly), related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• Lilly licenses the intellectual property, solanezumab, being evaluated in the research. Dr. Holtzman collaborated with Lilly to develop solanezumab. Dr. Holtzman could benefit financially if this study medication, which is one of the three study medications being tested, proves beneficial and is ultimately approved by the FDA.
• The research is partially supported by Lilly.
• As a member of the DIAN-TU Therapy Evaluation Committee (TEC), he could influence decisions made about the design of the study.
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA
The proposed grant will initiate a trial of 3 anti-amyloid drugs in individuals with known causative mutations for dominantly inherited Alzheimer's disease (AD). Although this dominantly inherited form of AD is rare, the symptoms and brain changes are similar to those observed in the far more common late-onset sporadic AD. The results of the trial provides a test of the amyloid hypothesis, and may delay, prevent or reverse cognitive impairment from AD.
Filed on September 23, 2013.
Tell us what you know about David Holtzman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Holtzman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly | $0 - $4,999 |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Therapeutics | $20,000 - $39,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | $20,000 - $39,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | $10,000 - $19,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.